Articles related to Pharmacy (Clinical/Hospital)

Across 14 health-system specialty pharmacies, pharmacist interventions were associated with an estimated $3.6 million in avoided medication costs over six months. The analysis used a structured attribution method to assess the likelihood that individual interventions altered treatment trajectories.

Medicare’s new GLP-1 Bridge Program expands lower-cost access to certain weight-loss medications for eligible beneficiaries. Concurrent ISMP guidance outlines common medication errors and counseling challenges as more patients initiate GLP-1 therapy.

A post-thyroidectomy patient’s LDL-C rose above 250 mg/dL during recurrent hypothyroidism and improved after euthyroidism returned. The case highlights medication adherence and secondary-cause review before lipid-therapy escalation.

The FDA has approved the first generic version of baloxavir marboxil, a single-dose influenza antiviral noninferior to oseltamivir, ahead of the 2026-2027 flu season.

Pediatric pharmacists recorded 1,130 antithrombotic-related interventions involving 26.4% of 2,264 critically ill children across 9 U.S. children’s hospitals during 697 shifts from July 2023 to November 2024, with 74.7% of those interventions occurring in the pediatric cardiac ICU and 90.4% of initiation and management interventions involving anticoagulant agents.

The Main Street Pharmacy Access Act (H.R. 3164/S. 2426), which would authorize Medicare reimbursement for pharmacist-provided testing and treatment of flu, strep, RSV, and COVID-19 in states that already permit those services, cleared the House Committee on Ways and Means on May 21 with more than 110 congressional co-sponsors and support from over 170 organizations.